Stockscreener 앱 받기
1.13
2.59%
-0.03
시장 영업 전:
1.13
전일 마감가:
$1.16
열려 있는:
$1.13
하루 거래량:
1.04M
Relative Volume:
0.39
시가총액:
$88.80M
수익:
-
순이익/손실:
$-37.34M
주가수익비율:
-0.8309
EPS:
-1.36
순현금흐름:
$-36.91M
1주 성능:
-11.02%
1개월 성능:
+11.88%
6개월 성능:
-14.39%
1년 성능:
+20.70%
1일 변동 폭
$1.10
$1.165
1주일 범위
$1.10
$1.36
52주 변동 폭
$0.772
$1.84
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
명칭
Sellas Life Sciences Group Inc
전화
(646) 200-5278
주소
7 TIMES SQUARE, NEW YORK, NY
SLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.13 | 88.80M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 개시 | Oppenheimer | Outperform |
| 2018-04-02 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 업그레이드 | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL
Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment - Yahoo Finance
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial - MSN
SELLAS reports promising DLBCL treatment trial results By Investing.com - Investing.com Nigeria
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewswire
3 AI Stocks Lawmakers Are Snapping Up Now - The Globe and Mail
SELLAS Reports Positive Phase 2a Data For SLS009 With Zanubrutinib In Relapsed/Refractory DLBCL - Nasdaq
SELLAS reports promising DLBCL treatment trial results - Investing.com
SELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL Patients - Nasdaq
SELLAS Life Sciences Group’s $25 Million Common Stock Offering - Global Legal Chronicle
SELLAS Life Sciences Group Inc (NASDAQ:SLS) stock crossing the finish line today - US Post News
Market Insight: SELLAS Life Sciences Group Inc (SLS)’s Notable Drop, Closing at 1.37 - The Dwinnex
Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - SETE News
SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - MarketBeat
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Stock Has Gained 38.89% Over The Month – Is There Room For Growth? – Marketing Sentinel - Marketing Sentinel
Orangekloud Technology Inc (NASDAQ: ORKT) Up 58.11% From 52-Week Low; YTD Falls -50.99% – Here’s What To Do Now – Marketing Sentinel - Marketing Sentinel
Stock Traders Buy Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - MarketBeat
Insider’s View: Deciphering SELLAS Life Sciences Group Inc (SLS)’s Financial Health Through Ratios - The Dwinnex
Market Analysts see SELLAS Life Sciences Group Inc [SLS] gaining to $18. Time to buy? - The DBT News
SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS) - Defense World
You Should Read This Analysis Before Investing in SELLAS Life Sciences Group Inc (NASDAQ:SLS) - US Post News
Sellas Life Sciences Group Announces $25 Million Registered Direct Offering - Defense World
Analysts Provide An Important Insights On SELLAS Life Sciences Group Inc (SLS) - Stocks Register
SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
SELLAS secures $25 million in registered direct offering By Investing.com - Investing.com South Africa
SELLAS secures $25 million in registered direct offering - MSN
SELLAS Life Sciences Group Announces $25 Million Registered - GlobeNewswire
Major Healthcare Investor Backs SELLAS with $25M DealHere's the Full Structure - StockTitan
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - Defense World
SELLAS Life Sciences Announces Positive Phase 3 Trial Results - TipRanks
SELLAS Life Sciences stock falls on GPS data (SLS:NASDAQ) - Seeking Alpha
SELLAS Life Sciences Announces Positive Outcome of Interim - GlobeNewswire
SELLAS Phase 3 AML Trial Shows Promising 13.5-Month Survival Data, Double Historical Average - StockTitan
Biotech CEO predicts 'revolutionary decade' in medicine through AI advancements - Fox News
SLS Stock Quote Price and Forecast - CNN
SELLAS Life Sciences amends executive severance agreements - MSN
SELLAS Life Sciences Group Inc (NASDAQ: SLS): Blank Check On Growth? - Stocks Register
SELLAS Life Sciences Group Approves Amendments to Change in Control Severance Agreements - Defense World
SELLAS Life Sciences amends executive severance agreements By Investing.com - Investing.com Australia
SELLAS Life Sciences Amends Severance for Key Executives - TipRanks
Analyze SELLAS Life Sciences Group Inc (NASDAQ: SLS) Before Investing. - Stocks Register
Geode Capital Management LLC Has $757,000 Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
SELLAS advances cancer drug trials, eyes key 2025 milestones - Investing.com
SELLAS advances cancer drug trials, eyes key 2025 milestones By Investing.com - Investing.com UK
Sellas Life Sciences Group Inc (SLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
0.33%
자본화:
|
볼륨(24시간):